P-143 Effect of oral magnesium supplementation on insulin sensitivity and blood pressure in apparently healthy overweight adults — a randomized double-blinded controlled trial

To evaluate the effects of probiotic (VSL#3) and omega-3 fatty acid on insulin sensitivity, blood lipids, and inflammation, we conducted a clinical trial in 60 overweight (BMI>25), healthy adults, aged 40–60 years. After initial screening the subjects were randomized into four groups with 15 per group. The four groups received, respectively, placebo, omega-3 fatty acid, probiotic VSL#3, or both omega-3 and probiotic, for 6 weeks. Blood and fecal samples were collected at baseline and after 6 weeks. The probiotic (VSL#3) supplemented group had significant reduction in total cholesterol, triglyceride, LDL, and VLDL and had increased HDL (P<0.05) value. VSL#3 improved insulin sensitivity (P<0.01), decreased hsCRP, and favorably affected the composition of gut microbiota. Omega-3 had significant effect on insulin sensitivity and hsCRP but had no effect on gut microbiota. Addition of omega-3 fatty acid with VSL#3 had more pronounced effect on HDL, insulin sensitivity and hsCRP. Subjects with low HDL, insulin resistance, and high hsCRP had significantly lower total lactobacilli and bifidobacteria count and higherE. coliand bacteroides count.

Download Full-text

Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate-induced hypertension in rats

Journal of Hypertension ◽

10.1097/00004872-200101000-00023 ◽

2001 ◽

Vol 19 (1) ◽

pp. 161-162 ◽

Cited By ~ 5

Author(s):

Klaus Kisters ◽

Martin Hausberg ◽

Markus Kosch

Keyword(s):

Blood Pressure ◽

Platelet Aggregation ◽

Calcium Handling ◽

Magnesium Supplementation ◽

Deoxycorticosterone Acetate ◽

Induced Hypertension ◽

Oral Magnesium

Download Full-text

Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial

European Journal of Clinical Nutrition ◽

10.1038/sj.ejcn.1602475 ◽

2006 ◽

Vol 61 (1) ◽

pp. 54-60 ◽

Cited By ~ 39

Author(s):

C Gontijo-Amaral ◽

M A G O Ribeiro ◽

L S C Gontijo ◽

A Condino-Neto ◽

J D Ribeiro

Keyword(s):

Controlled Trial ◽

Magnesium Supplementation ◽

Double Blind ◽

Asthmatic Children ◽

Oral Magnesium

Download Full-text

Changes of Blood Pressure and Hemodynamic Parameters after Oral Magnesium Supplementation in Patients with Essential Hypertension—An Intervention Study

Nutrients ◽

10.3390/nu10050581 ◽

2018 ◽

Vol 10 (5) ◽

pp. 581 ◽

Cited By ~ 1

Author(s):

Nikolina Banjanin ◽

Goran Belojevic

Keyword(s):

Blood Pressure ◽

Essential Hypertension ◽

Intervention Study ◽

Hemodynamic Parameters ◽

Magnesium Supplementation ◽

Oral Magnesium

Download Full-text

Microbial Interventions to Control And Reduce Blood Pressure In Australia (Microbia): Rationale And Design of A Double-Blinded Randomised Cross-Over Placebo Controlled Trial

10.21203/rs.3.rs-149397/v1 ◽

2021 ◽

Author(s):

Dakota Rhys-Jones ◽

Rachel Climie ◽

Hamdi Jama ◽

Paul Gill ◽

Geoffrey Head ◽

...

Keyword(s):

Blood Pressure ◽

Clinical Trial ◽

Gut Microbiota ◽

Resistant Starch ◽

Corn Starch ◽

Controlled Trial ◽

Short Chain Fatty Acids ◽

Reduce Blood Pressure ◽

Clinical Trial Registry ◽

Double Blinded

Abstract Background: Hypertension is a prevalent chronic disease worldwide that remains poorly controlled. Recent studies support the concept that the gut microbiota is involved in the development of hypertension, and that dietary fibre intake may act through the gut microbiota to lower blood pressure (BP). Resistant starch is a type of prebiotic fibre which is metabolized by commensal bacteria in the colon to produce short-chain fatty acids (SCFA), including acetate, propionate, and butyrate. Previous work in pre-clinical models provide strong evidence that both prebiotic fibre as well as SCFAs (i.e. postbiotics) can prevent the development of hypertension. The aim of this clinical trial is to determine if acetylated and butyrylated modified resistant starch can decrease BP of hypertensive individuals via the modulation of the gut microbiota and release of high levels of SCFAs. Methods: This is a phase IIa double-blinded, randomised, cross-over, placebo controlled trial. Participants are randomly allocated to receive either a diet containing 40g/day of the modified resistant starch or placebo (corn starch or regular flour) for three weeks on each diet, with a three week washout period between the two diets. BP is measured in the office, at home, and using a 24 hour ambulatory device. Arterial stiffness is measured using carotid-to-femoral pulse wave velocity. Our primary endpoint is a reduction in ambulatory daytime systolic BP. Secondary endpoints include changes to circulating cytokines, immune markers, and modulation to the gut microbiome. Discussion: The findings of this study will provide the first evidence for the use of a combination of pre- and postbiotics to lower BP in humans. The results are expected at the end of 2021.Trial registration: Australia and New Zealand Clinical Trial Registry ACTRN12619000916145, registered on 1/07/2019.

Download Full-text